Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.82 |
| ▸ | TUBB | P07437 | 4/20 | 0.82 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.82 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.82 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.82 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.82 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.82 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.82 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.82 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.82 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.82 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.82 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.82 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.82 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | P4HB | P07237 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13032760 | 1.00 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14850594 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15046116 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22203062 | 0.95 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13024629 | 0.95 | TUBB4A (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12530882 | 0.94 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18758159 | 0.94 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29417872 | 0.94 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12530451 | 0.94 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18746261 | 0.94 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20200129632-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-10626172-B2 | Antibody drug conjugates | NOVARTIS AG (CH) | 2020-04-21 | — | — | US | disclosed |
| US-20190345250-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-20190119375-A1 | Antibody Drug Conjugates | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-10238748-B2 | Anti-CDH6 antibody drug conjugates | NOVARTIS AG (CH) | 2019-03-26 | — | — | US | disclosed |
| US-10005836-B2 | Antibody drug conjugates | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-8142784-B2 | Antibody-drug conjugates and methods | GENENTECH, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-7855275-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-7662936-B2 | detect, screen, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates, antibodies, and fragments and metabolites thereof, by affinity separation, chromatography, and mass spectrometry; monomethyl auristatin drug and a thio-ether linkage | GENENTECH, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100003766-A1 | screening cysteine engineered antibodies for thiol reactivity; using antibodies or antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor or cancer cells | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090286258-A1 | ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY | GENENTECH, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7521541-B2 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENETECH INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | GENENTECH, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345250-A1 | ANTIBODY DRUG CONJUGATES | FGFR2, FGFR3, FGFR4 | TUBB4A 538/4885TUBB 479/4885TUBA3C 447/4885 |
| US-20190119375-A1 | Antibody Drug Conjugates | EPCAM, CDH1, CD44 | TUBB4A 270/4885TUBB 316/4885TUBA3C 202/4885 |
| US-10626172-B2 | Antibody drug conjugates | EPCAM, CDH1, CD44 | TUBB4A 270/4885TUBB 316/4885TUBA3C 202/4885 |
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | CTH, LNPEP, CARS1 | TUBB4A 843/4885TUBB 781/4885TUBA3C 393/4885 |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | ERBB2, EGFR, ERBB4 | TUBB4A 1049/4885TUBB 1421/4885TUBA3C 1997/4885 |
| US-20200129632-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CD44, ABL1 | TUBB4A 254/4885TUBB 196/4885TUBA3C 124/4885 |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | CCR7, BCL6, CXCR3 | TUBB4A 746/4885TUBB 607/4885TUBA3C 472/4885 |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | CTH, LNPEP, CARS1 | TUBB4A 843/4885TUBB 781/4885TUBA3C 393/4885 |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | TUBB4A 2535/4885TUBB 2712/4885TUBA3C 1054/4885 |
| US-10005836-B2 | Antibody drug conjugates | EPCAM, CDH1, CD44 | TUBB4A 270/4885TUBB 316/4885TUBA3C 202/4885 |
| US-10238748-B2 | Anti-CDH6 antibody drug conjugates | EPCAM, CD44, CDH1 | TUBB4A 282/4885TUBB 368/4885TUBA3C 302/4885 |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | ALB, LNPEP, CSTB | TUBB4A 104/4885TUBB 35/4885TUBA3C 537/4885 |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | ERBB2, EGFR, ERBB4 | TUBB4A 1372/4885TUBB 1593/4885TUBA3C 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.